Skip to main content

Hologic Value Stock - Dividend - Research Selection

Hologic

ISIN: US4364401012 , WKN: 879100

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. It offers Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and related products, and accessories comprising digital and film-based mammography systems; computer-aided detection for mammography; minimally invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. In addition, it offers Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D, a software product that provides 2D images; Selenia digital mammography platform; and SecurView Workstation. Further, it provides SculpSure, MonaLisa Touch, Vectus diode, and Cellulaze laser devices; PicoSure and Icon aesthetic systems; MedLite, RevLite, Cynergy, Elite, and SmartLipo products; and system components. Additionally, it offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient\'s extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Hologic (HOLX) Stock Drops Despite Market Gains: Important Facts to Note

2024-04-22
Hologic (HOLX) reachead $75.36 at the closing of the latest trading day, reflecting a -0.03% change compared to its last close.

Is It Time To Consider Buying Hologic, Inc. (NASDAQ:HOLX)?

2024-04-22
Today we're going to take a look at the well-established Hologic, Inc. ( NASDAQ:HOLX ). The company's stock saw its...

Goldman’s buybacks basket: Buyback growth will be 13% in 2024

2024-04-22
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

This CEO has battled billionaire activist Carl Icahn twice — here's his advice to Disney CEO Bob Iger

2024-04-21
Illumina chairman and Hologic CEO Stephen MacMillan is no stranger to dealing with well-known activist investors.

Hologic (HOLX) Q2 Earnings Might Rise on GYN Surgical Growth

2024-04-19
Hologic's (HOLX) second-quarter fiscal 2024 performance is likely to be driven by the GYN Surgical portfolio.

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

2024-04-19
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Agree To Purchase Hologic At $55, Earn 1.6% Annualized Using Options

2024-04-18
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

ClearBridge Appreciation ESG Strategy Q1 2024 Portfolio Manager Commentary

2024-04-18
Although technology and AI remain a dominant part of the market narrative, benchmark performance has broadened significantly in the current rally.

Hologic (HOLX) to Report Q2 Earnings: What's in the Cards?

2024-04-17
Strength in Molecular Diagnostics business and GYN Surgical is likely to have driven Hologic's (HOLX) fiscal second-quarter performance.

ClearBridge Sustainability Leaders Strategy Q1 2024 Portfolio Manager Commentary

2024-04-17
U.S. equities continued their upward march in the first quarter as the momentum rally, begun following November’s inflation print, showed few signs of flagging.